Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 6, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Cowen 38th Annual Healthcare Conference on March 13, 2018 at 11:20 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
CTP-543 On Track to Report Topline Phase 2a Results in Alopecia Areata by Year-End New Neuropsychiatric Product Candidate Poised to Enter Clinical Development in 2018 Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Mar. 1, 2018-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia
CTP-692 Poised to Enter Clinical Development in 2018 as an Adjunctive Treatment of Schizophrenia Conference Call Scheduled Tomorrow at 8:30 a.m. ET for Company Update and 2017 Financial Results LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 28, 2018-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018
LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 21, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017 , on Thursday, March 1, 2018 , before the U.S. financial markets open.
View HTML
Toggle Summary Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543.
View HTML
Toggle Summary FDA Grants Fast Track Designation to Concert Pharmaceuticals' CTP-543 for the Treatment of Alopecia Areata
CTP-543 is a Novel JAK Inhibitor in Phase 2 for Alopecia Areata as Potential First-in-Class Treatment LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a
View HTML
Toggle Summary Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company's Post Grant Review (PGR) petition challenging the validity of U.S. Patent No.
View HTML
Toggle Summary Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018 . Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry.
View HTML
Toggle Summary Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017 .
View HTML
Toggle Summary Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. "This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our
View HTML